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Letters to the Editor
Body Size and the
Early Mortality Gender
Gap in Coronary Artery
Bypass Grafting Surgery
Humphries et al. (1) investigated gender differences in 30-day
mortality after isolated coronary artery bypass grafting (CABG) for
the entire province of British Columbia from 1991 to 2004. The
authors report a substantial trend for improved early CABG
mortality in women over this 14-year period. Yet there remains a
significant 42% worse 30-day mortality in women even after
adjustment for differences in age, comorbid conditions, and surgi-
cal factors. Lastly, they report that this gender gap in early CABG
outcomes is decreased and is no longer statistically significant
(odds ratio 1.26, 95% confidence interval 0.96 to 1.64) when their
data is adjusted to body surface area (BSA). The authors explained
the latter by a presumed association between lower BSA and
smaller coronary vessel size.
We concur with the authors that patients with lower BSA are
more likely to have smaller coronary targets that are more difficult
to revascularize with potential adverse implications on outcomes.
This, however, ignores other important factors that are associated
with body size and are especially true in case of CABG with
cardiopulmonary bypass such as in their series (97% on-pump). A
strong association between small body size—disproportionately
represented by women—and greater on-pump hemodilution and
more frequent administration of packed red blood cell (RBC) units
is well established (2,3). Worse early CABG outcomes have been
associated with both lower on-pump hematocrits (2–4) and RBC
transfusions (5,6). We contend that the authors’ reported 30-day
mortality odds ratio of 1.26 in women compared with men would
be further reduced if their multivariate adjustment included he-
modilutional anemia and transfusion data. This perspective is
important, because in contrast to coronary vessel size, which is a
fixed patient characteristic, both of these size-related risk factors
are potentially modifiable. Specifically, hemodilutional anemia and
related use of blood products may be mitigated through specific
practices such as: 1) avoidance of cardiopulmonary bypass (off-
pump surgery); 2) use of miniaturized bypass circuits combined
with retrograde autologous priming; and/or 3) implementation of
conservative transfusion policies.
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Reply
We thank Drs. Habib and Zacharias for their thoughtful com-
ments on our manuscript (1). First it is important to clarify that the
significant 42% higher 30-day mortality in women reported in our
study refers to the overall 14-year time frame of the study and does
not imply that a 42% difference still persists at the end of our study
period. Quite the contrary, the gap narrowed significantly.
We certainly agree with the authors that coronary vessel size is
not the only important factor associated with body size. Specifi-
cally, the adverse effects of greater on-pump hemodilution and
more frequent administration of packed red blood cells in patients
with small body size suggests that women would be differentially
affected. These aspects would be interesting to evaluate, especially
because they are not intrinsic patient characteristics but potentially
modifiable processes of care. Unfortunately, our database did not
reliably capture this information.
Nevertheless, it is important to point out that even if we could
undertake the suggested analysis, any attenuation in the gender
difference that might result from adjustment for red blood cell
transfusions and on-pump hematocrit would be unlikely to explain
the significant decline in female 30-day mortality over the last 14
years. To attribute the observed decline in mortality to these
factors would necessitate a very large decrease in the prevalence of
hemodilutional anemia and/or use of blood products differentially
in women compared with men. Alternatively, because these
characteristics are associated with body size, we would have had to
observe a very sharp decline in the proportion of women versus
men with small body size. As shown in Table 3 of our manuscript,
the proportion of women with small body size changed very little
in our dataset over the last 14 years.
In light of the evidence that hemodilution (2,3) and frequent
transfusions are associated with adverse outcomes (4,5), changes in
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